Psychedelic Alpha Bulletin 205: AbbVie targets Gilgamesh, US psychedelic use rises, FDA moves to ban 7-OH kratom compound, and Sinema is selling what

Psychedelic Alpha Bulletin 205 connects multiple headlines across investment, policy, and market signals in the psychedelic and kratom space. AbbVie is reported to be looking at Gilgamesh as part of ongoing interest in developing psychedelics and related therapies. The bulletin also flags that psychedelic use is increasing in the US, signaling growing mainstream demand and attention. Regulatory and safety news is a major focus, including an FDA move aimed at banning a specific kratom-related compound (7-OH). The roundup also addresses what Sinema is selling, tying political and commercial activity to the broader attention on these substances.